About Veracor Capital

    Strategic Capital for Healthcare Transformation

    Veracor Capital is the fund formation, fund management, and investor relations division of Veracor Group Holdings.

    Who We Are

    We deploy strategic capital into healthcare transformation opportunities, with a focus on Signal-Based Medicine and women-led healthcare ventures.

    Our mission is to provide sophisticated investors access to a vertically integrated healthcare ecosystem with proven methodologies, operational infrastructure, and demonstrated clinical outcomes.

    Unlike traditional healthcare investments that optimize for recurring revenue, we invest in companies that actually heal patients — creating value through outcomes, not dependency.

    Veteran Owned BusinessVeteran-Owned & Operated

    Part of Veracor Group Holdings

    Veracor Capital is the investment arm of a larger healthcare ecosystem, providing access to proprietary deal flow and operational expertise.

    Focus on Signal-Based Medicine

    Our investment thesis centers on healthcare solutions that identify and correct biological dysfunction at the cellular level.

    Impact-Aligned Returns

    We prove that investment returns and meaningful impact aren't competing priorities — they're aligned through better patient outcomes.

    Our Story

    Operations First. Fund Second.

    Most funds raise capital and then go searching for deals. We spent 20 years building healthcare companies — then created a fund to scale what already works.

    2005

    Kenton Gray begins developing Signal-Based Medicine protocols in clinical practice.

    2010

    KureCare wound care division launches, achieving 95% healing rates exceeding Medicare benchmarks.

    2018

    EliteMD medical director network established with nationwide coverage.

    2020

    Pure Pak acquired — 150,000 sq ft FDA-registered contract manufacturer completing vertical integration.

    2022

    Veracor Capital formed to deploy institutional capital into the ecosystem we already built.

    2024

    RIIZE STRIPS generates $3.6M in first-year revenue. Strategic pivot to DTC begins.

    2025

    Build year: KureCare hits $4.6M revenue. RIIZE retooled for DTC. KureOS AI enters development.

    2026

    Launch year: Multi-fund strategy goes live. RIIZE DTC nationwide. Reg CF opens retail access.

    Signal-Based Medicine cellular healing visualization
    Our Mission

    Healing at the Cellular Level

    Signal-Based Medicine represents a paradigm shift in healthcare — identifying and correcting biological dysfunction at its source. Our portfolio companies don't just treat symptoms; they restore function and create lasting health outcomes.

    95%

    Success Rate

    47K+

    Patients Healed

    Who We Serve

    Our Investor Partners

    Accredited Investors

    $1M+ net worth, seeking alternative investments

    Portfolio diversification, impact + returns

    Family Offices

    Multi-generational wealth, long-term horizon

    Thematic healthcare exposure

    Institutional LPs

    Pension funds, endowments, sovereign wealth

    Uncorrelated returns, ESG alignment

    Impact Investors

    Mission-aligned capital deployment

    Measurable healthcare outcomes

    Global Media Recognition

    As Featured In

    major media outlets worldwide

    The New York Times
    Forbes
    Bloomberg
    BUSINESS INSIDER
    Los Angeles Times
    WIRED
    Sports Illustrated
    USA TODAY

    Learn More About Our Investment Approach

    Discover why Signal-Based Medicine represents the future of healthcare investing.